OncoMatch/Clinical Trials/NCT06678659
A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer
Is NCT06678659 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies REC-1245 for unresectable.
Treatment: REC-1245 — This is a multi-center, open-label study to investigate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary activity of REC-1245 administered orally on a once daily (QD) schedule in participants with unresectable, locally advanced, or metastatic solid tumors.
Check if I qualifyExtracted eligibility criteria
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: systemic anti-cancer treatment
Have experienced progressive disease, relapsed disease, or be intolerant to at least one established standard systemic anti-cancer treatment for a given tumor type, or have been considered ineligible for standard therapy.
Cannot have received: RBM39 degrader
Received treatment with another RBM39 degrader
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- City of Hope · Duarte, California
- Cleveland Clinic · Cleveland, Ohio
- SCRI Oncology Partners - PPDS · Nashville, Tennessee
- START Mountain Region · West Valley City, Utah
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify